Opendata, web and dolomites

Hemstem SIGNED

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hemstem project word cloud

Explore the words cloud of the Hemstem project. It provides you a very rough idea of what is the project "Hemstem" about.

intensity    transplantation    vivo    difficult    resistance    strategies    screens    subpopulations    30    hscs    mo    similarity    myeloid    homing    bm    zebrafish    explores    inhibit    surviving    ways    displace    curative    clinical    leukemic    stemness    treatment    protective    simultaneously    im    healthy    immunotherapy    supporting    fact    chemotherapy    prove    interactions    experimental    immune    allogeneic    human    natural    revolutionize    stem    decades    lecular    acute    survive    self    costly    advantages    molecular    diagnosis    home    paradigm    surveillance    governing    hematopoietic    small    inborn    severe    visualize    expansion    mutations    patients    rationale    mutational    marrow    niche    affinity    unable    eradicating    shift    cells    lscs    oncogenic    devastating    profiling    cell    leukemia    bone    wealth    competitors    modify    conserved    signaling    hsc    hematopoiesis    malignant    regulates    uses    renewal    therapy    niches    lsc    insights    disease    despite    crude    instead    treatments    evolutionary    molecules    wnt    patient    aml   

Project "Hemstem" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙984˙240 €
 EC max contribution 1˙984˙240 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 1˙984˙240.00

Map

 Project objective

Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects. One reason why the wealth of molecular and experimental knowledge has so far been unable to revolutionize treatments is the fact that AML is driven by small subpopulations of so-called leukemic stem cells (LSCs), which survive chemotherapy and immune surveillance. LSCs have growth advantages induced by oncogenic mutations, but are in many ways similar to healthy hematopoietic stem cells (HSCs). This similarity makes it difficult to target LSCs without simultaneously eradicating HSCs and healthy hematopoiesis derived from these cells. Like HSCs, LSCs home to protective bone marrow (BM) niches promoting stemness and therapy resistance and modify them to displace HSCs and promote their own expansion. This proposal explores strategies to target LSCs based on understanding these interactions. In Aim 1 we investigate how WNT signaling, an evolutionary conserved pathway governing stem cell self-renewal, regulates interactions between leukemic and healthy hematopoietic (stem) cells. In Aim 2, we propose to inhibit the in vivo expansion of LSCs by enhancing self-renewal and niche affinity in their natural competitors, the healthy stem cells with inborn BM homing ability. Aim 3 uses zebrafish to visualize LSC-HSC interactions and screens for molecules supporting healthy instead of (pre-) malignant hematopoiesis. Our studies will im-prove the knowledge on the complex interactions between LSCs and HSCs and provide a rationale for novel treatments that might lead to a paradigm-shift in the clinical management of AML.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More